| Vadodara-based Alembic posted a total revenue of 572.42 crore for the financial year 2004-05, down 6.7 per cent from Rs 613.82 crore in the previous financial year. This was mainly on account of lower domestic formulations sales during the year. PBT for the year stood at Rs 52.62 crore (Rs 43.12 crore), and PAT rose 62 per cent stood at Rs 50.65 crore (Rs 31.26 crore). |
| A company statement said it expects to achieve better results in the current year (2005-06) on the back of better performance of domestic formulation business as well as improvement in API business. Overall, the company expects sales to grow 16-18 per cent and PAT to rise 30 per cent. Alembic has stepped up its research expenses from Rs 19.30 crore in 20003-04 to Rs 31.12 crore during 2004-05. |
| Aventis Q1 net down 26.2% |
| Aventis Pharma has posted 26.2 per cent decline in net profit at Rs 23.60 crore for the quarter ended March 31, 2005 as compared with Rs 32 crore for the quarter ended March 31, 2004. Total income increased to Rs 181.50 crore for the quarter ended March 31, 2005 as against Rs 171.20 crore in the same period last year. |
| Cadila Q4 net down 5.3% |
| Zydus Cadila Healthcare posted net sales of Rs 1063.40 crore for 2004-05, lower than net sales of Rs 1172.27 posted in the previous year. Total income stood at Rs 1141.90 crore (Rs 1244.15 crore). PBT stood at Rs 162.80 crore (Rs 172.37 crore), while PAT stood at Rs 143.80 crore, down 5.3 per cent from Rs 151.88 crore. Net profit for the year 2004-05 fell to Rs 131.40 crore, down from Rs 142.83 crore for 2003-04. |
| The EPS for the year 2004-05 stood at Rs 20.93 as against an EPS of Rs 22.75 for the previous year. However, a rise in reserves has been reported in the 2004-05 at Rs 583 crore as against reserves of Rs 550.6 crore for the previous year. |
| Carborundum Q4 net down 11% |
| Carborundum Universal registered a net profit of Rs 13.46 crore in the fourth quarter of 2004-05, down 11.21 per cent from the last year's Q4 profit of Rs 15.16 crore. The governing board has recommended a bonus issue of equity in ratio of one share for every share held. It has also recommended a dividend of 100 per cent on equity (face value Rs 2). |
| The company's sales for the fourth quarter of 2004-05 was up 9.69 per cent to Rs 101.87 crore (Rs 92.78 crore). The company recorded a net profit of Rs 38.43 crore in 2004-05, higher by 21.19 per cent in relation to the previous year's Rs 31.71 crore. The sales for 2004-05 was up 13.46 per cent at Rs 356.46 crore (Rs 314.16 crore). |
Top Section
Explore Business Standard